Denna sida på svenska

Malin Wickström

Assistant professor

Visiting address : Karolinska Universitetssjukhuset, Q6:05 17176 Stockholm, Sweden
Postal address : Department of Women's and Children's Health (KBH), K6, Division of Pediatric Oncology, Karolinska Universitetssjukhuset, Q6:05 17176 Stockholm, Sweden
Delivery address : Karolinska Universitetssjukhuset, Q6:05 17176 Stockholm, Sweden

Publications

In vitro and in vivo activity of melflufen (J1)in lymphoma
Delforoush M, Strese S, Wickström M, Larsson R, Enblad G, Gullbo J
BMC cancer 2016;16():263-

Planar cell polarity gene expression correlates with tumor cell viability and prognostic outcome in neuroblastoma
Dyberg C, Papachristou P, Haug Bh, Lagercrantz H, Kogner P, Ringstedt T, et al
BMC cancer 2016;16():259-

Wingless/β-catenin signaling as a modulator of chemoresistance in cancer
Johnsen Ji, Wickström M, Baryawno N
Molecular & cellular oncology 2016;3(2):e1131356-

Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance
Wickström M, Dyberg C, Milosevic J, Einvik C, Calero R, Sveinbjörnsson B, et al
Nature communications 2015;6():8904-

Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment
Eriksson E, Wickström M, Perup Ls, Johnsen Ji, Eksborg S, Kogner P, et al
Journal of the National Cancer Institute 2014;106(3):djt459-

The impact of S6K1 kinase on neuroblastoma cell proliferation is independent of GLI1 signaling
Diao Y, Rahman Mf, Villegas Ve, Wickström M, Johnsen Ji, Zaphiropoulos Pg
BMC cancer 2014;14():600-

Alternative cytotoxic effects of the postulated IGF-IR inhibitor picropodophyllin in vitro
Wu X, Sooman L, Wickström M, Fryknäs M, Dyrager C, Lennartsson J, et al
Molecular cancer therapeutics 2013;12(8):1526-36

Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance
Fryknäs M, Gullbo J, Wang X, Rickardson L, Jarvius M, Wickström M, et al
BMC cancer 2013;13():374-

Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo
Wickström M, Dyberg C, Shimokawa T, Milosevic J, Baryawno N, Fuskevåg Om, et al
International journal of cancer 2013;132(7):1516-24

The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo
Strese S, Wickstrom M, Fuchs Pf, Fryknas M, Gerwins P, Dale T, et al
BIOCHEMICAL PHARMACOLOGY 2013;86(7):888-95

In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues
Haglund C, Aleskog A, Nygren P, Gullbo J, Hoglund M, Wickstrom M, et al
CANCER CHEMOTHERAPY AND PHARMACOLOGY 2012;69(3):697-707

The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia
Eriksson A, Hermanson M, Wickström M, Lindhagen E, Ekholm C, Jenmalm Jensen A, et al
Blood cancer journal 2012;2():e81-

Wig-1, a novel regulator of N-Myc mRNA and N-Myc-driven tumor growth
Vilborg A, Bersani C, Wickstrom M, Segerstrom L, Kogner P, Wiman Kg
CELL DEATH & DISEASE 2012;:e298-

Aminopeptidase N (CD13) as a target for cancer chemotherapy
Wickstrom M, Larsson R, Nygren P, Gullbo J
CANCER SCIENCE 2011;102(3):501-8

Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo
Segerstrom L, Baryawno N, Sveinbjornsson B, Wickstrom M, Elfman L, Kogner P, et al
INTERNATIONAL JOURNAL OF CANCER 2011;129(12):2958-65

Inhibitors and promoters of tubulin polymerization: Synthesis and biological evaluation of chalcones and related dienones as potential anticancer agents
Dyrager C, Wickstrom M, Friden-saxin M, Friberg A, Dahlen K, Wallen Eaa, et al
BIOORGANIC & MEDICINAL CHEMISTRY 2011;19(8):2659-65

Phenotype-based drug screening in primary ovarian carcinoma cultures identifies intracellular iron depletion as a promising strategy for cancer treatment
Gullbo J, Fryknas M, Rickardson L, Darcy P, Hagg M, Wickstrom M, et al
BIOCHEMICAL PHARMACOLOGY 2011;82(2):139-47

Tissue Factor/FVIIa prevents the extrinsic pathway of apoptosis by regulation of the tumor suppressor Death-Associated Protein Kinase 1 (DAPK1)
Aberg M, Johnell M, Wickstrom M, Siegbahn A
THROMBOSIS RESEARCH 2011;127(2):141-8

High Content Screening for Inhibitors of Protein Interactions and Post-translational Modifications in Primary Cells by Proximity Ligation
Leuchowius Kj, Jarvius M, Wickstrom M, Rickardson L, Landegren U, Larsson R, et al
MOLECULAR & CELLULAR PROTEOMICS 2010;9(1):178-83

Synthesis and Characterization of a Multi Ring-Fused 2-Pyridone-Based Fluorescent Scaffold
Sellstedt M, Nyberg A, Rosenbaum E, Engstrom P, Wickstrom M, Gullbo J, et al
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY 2010;:6171-6178

The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan
Wickstrom M, Viktorsson K, Lundholm L, Aesoy R, Nygren H, Sooman L, et al
BIOCHEMICAL PHARMACOLOGY 2010;79(9):1281-90

The Cytotoxic Agents NSC-95397, Brefeldin A, Bortezomib and Sanguinarine Induce Apoptosis in Neuroendocrine Tumors In Vitro
Larsson De, Wickstrom M, Hassan S, Oberg K, Granberg D
ANTICANCER RESEARCH 2010;30(1):149-56

Cytotoxic Effects of Cardiac Glycosides in Colon Cancer Cells, Alone and in Combination with Standard Chemotherapeutic Drugs
Felth J, Rickardson L, Rosen J, Wickstrom M, Fryknas M, Lindskog M, et al
JOURNAL OF NATURAL PRODUCTS 2009;72(11):1969-74

Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo
Paimberg E, Johnsen Ji, Paulsson J, Gleissman H, Wickstrom M, Edgren M, et al
INTERNATIONAL JOURNAL OF CANCER 2009;124(5):1227-34

Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia
Lindhagen E, Eriksson A, Wickstrom M, Danielsson K, Grundmark B, Henriksson R, et al
EUROPEAN JOURNAL OF HAEMATOLOGY 2008;81(5):344-53

Simvastatin induces apoptosis in human breast cancer cells in a NF kappa B-dependent manner and abolishes the anti-apoptotic signaling of TF/FVIIa and TF/FVIIa/FXa
Aberg M, Wickstrom M, Siegbahn A
THROMBOSIS RESEARCH 2008;122(2):191-202

Simvastatin reduces the production of prothrombotic prostasomes in human prostate cancer cells
Aberg M, Johnell M, Wickstrom M, Widunder A, Siegbahn A
THROMBOSIS AND HAEMOSTASIS 2008;100(4):655-62

The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro
Wickstrom M, Haglund C, Lindman H, Nygren P, Larsson R, Gullbo J
INVESTIGATIONAL NEW DRUGS 2008;26(3):195-204

Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo
Ponthan F, Wickstrom M, Gleissman H, Fuskevag Om, Segerstrom L, Sveinbjornsson B, et al
CLINICAL CANCER RESEARCH 2007;13(3):1036-44

Image-based screening for the identification of novel proteasome inhibitors
Rickardson L, Wickstrom M, Larsson R, Lovborg H
JOURNAL OF BIOMOLECULAR SCREENING 2007;12(2):203-10

Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients
Wickstrom M, Danielsson K, Rickardson L, Gullbo J, Nygren P, Isaksson A, et al
BIOCHEMICAL PHARMACOLOGY 2007;73(1):25-33

The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo
Wickstrom M, Johnsen Ji, Ponthan F, Segerstrom L, Sveinbjornsson B, Lindskog M, et al
MOLECULAR CANCER THERAPEUTICS 2007;6(9):2409-17

Phenotype-based screening of mechanistically annotated compounds in combination with gene expression and pathway analysis identifies candidate drug targets in a human squamous carcinoma cell model
Fryknas M, Rickardson L, Wickstrom M, Dhar S, Lovborg H, Gullbo J, et al
JOURNAL OF BIOMOLECULAR SCREENING 2006;11(5):457-68

Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1
Gullbo J, Wickstrom M, Tullberg M, Ehrsson H, Lewensohn R, Nygren P, et al
JOURNAL OF DRUG TARGETING 2003;11(6):355-63

Show all publications